Received 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
|
|
- Allen Jordan
- 6 years ago
- Views:
Transcription
1 JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p Vol. 47, No /09/$ doi: /jcm Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007) Shawn A. Messer, 1 * Gary J. Moet, 1 Jeffrey T. Kirby, 1 and Ronald N. Jones 1,2 JMI Laboratories, North Liberty, Iowa, 1 and Tufts University School of Medicine, Boston, Massachusetts 2 Received 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009 Results from the SENTRY international fungal surveillance program for 2006 to 2007 are presented. A total of 1,448 Candida sp., 49 Aspergillus fumigatus, and 33 Cryptococcus neoformans isolates were obtained from infected sterile-site sources in patients on five continents. Reference susceptibility was determined for anidulafungin, caspofungin, 5-flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, and amphotericin B by CLSI methods. The implementation of standardized antifungal testing methods for Candida spp. and Cryptococcus spp.(1, 2) and the recent development of testing methods for the filamentous fungi (3, 4) have facilitated the generation of meaningful data to detect and assess resistance to the current clinical armamentarium of antifungal agents. The use of these methods in global longitudinal surveillance programs has been useful in detecting emerging, rarely encountered yeast or mold organisms displaying decreased susceptibility to contemporary antifungal compounds (12, 16) and for monitoring the distribution of yeast and mold species with innate resistance profiles. We summarize here the results of the global SENTRY Antimicrobial Surveillance Program (2006 to 2007) comparing the activities of eight currently marketed antifungal agents tested against clinical isolates from North America, Europe, Latin America, and the Asia-Pacific (APAC) region, with susceptibilities interpreted by using established CLSI breakpoint criteria, where available (1, 3). The collection of yeasts included Candida albicans (771 isolates), C. parapsilosis (238 isolates), C. glabrata (202 isolates), C. tropicalis (157 isolates), C. krusei (29 isolates), C. lusitaniae (14 isolates), C. guilliermondii (9 isolates), C. dubliniensis (7 isolates), C. famata (6 isolates), C. kefyr (5 isolates), and C. pelliculosa (4 isolates). The collection also included C. neoformans (33 isolates), and of the 61 molds, only Aspergillus fumigatus (49 isolates) is represented. All yeast and mold isolates were identified at the participating medical centers by the established methods in use at each institution. Isolates were requested to be from bloodstream infections, taken in consecutive order, and limited to one isolate per patient. The rates of occurrence in participating laboratories could then be detected * Corresponding author. Mailing address: Molecular Epidemiology and Fungus Testing Laboratory, Department of Pathology, University of Iowa, Iowa City, IA Phone: (319) Fax: (319) messers@healthcare.uiowa.edu. Published ahead of print on 22 April by a prevalence mode. Confirmation of species identification was performed at the central reference laboratory by using Vitek (biomérieux, St. Louis, MO) and by conventional reference methods (5, 17). Anidulafungin (4, 6, 7, 9, 10, 12, 14; Eraxis package insert [Pfizer, Inc., New York, NY, 2007]), voriconazole (Pfizer, Inc., New York, NY), amphotericin B, fluconazole, itraconazole, and 5-flucytosine (5-FC) (Sigma Chemical Co., St. Louis, MO) were obtained as standard powders. Caspofungin (Merck Research Laboratories, Rahway, NJ), and posaconazole (Schering-Plough Research Institute, Kenilworth, NJ) were prepared according to CLSI guidelines at TREK Diagnostics (Cleveland, OH) (1, 3). The final concentration ranges were as follows: anidulafungin, to 32 g/ml; caspofungin, to 16 g/ml; amphotericin B, 0.12 to 8 g/ml; 5-FC, 0.5 to 64 g/ml; fluconazole, 0.5 to 64 g/ml; itraconazole, to 2 g/ml; posaconazole, 0.06 to 8 g/ml; voriconazole, 0.06 to 8 g/ml. The dilution scheme was selected to maximize capture of the MIC 50 (MIC for 50% of the strains tested) and MIC 90 for wild-type and resistant mutant populations and varied by agent. Further, the ranges of newer or investigational agents were expanded in order to identify populations resistant to these newer agents. Micafungin powder was not yet available from the manufacturer at the commencement of testing. The absence of micafungin in comparison with the other available echinocandins is a limitation of this study. Broth microdilution testing for yeasts followed standardized procedures described in the CLSI M27-A3 reference method (1, 2). All of the filamentous fungi were tested under conditions described for the CLSI M38-A2 reference method (3, 4). Quality control isolates C. krusei ATCC 6258, C. parapsilosis ATCC 22019, and C. tropicalis ATCC 750 from the American Type Culture Collection were used as recommended (CLSI), and all results were observed within previously published ranges (1 3, 4, 7). All panels were incubated in enclosed, humid containers at 35 C and visualized with a reading mirror at 24 h (echinocandins) and 1942
2 VOL. 47, 2009 NOTES 1943 TABLE 1. In vitro antifungal agent susceptibilities of Candida and Cryptococcus isolates collected by the SENTRY Program in 2006 to 2007 Species (no. of isolates) and drug MIC 50 /MIC 90 ( g/ml) MIC range ( g/ml) % by category a S SDD R b All Candida spp. (1,448) c Anidulafungin 0.03/ Caspofungin 0.12/ Amphotericin B 0.5/ FC 0.5/ (2.2) 1.9 Fluconazole 0.5/ Itraconazole 0.06/ Posaconazole 0.06/ Voriconazole 0.06/ C. albicans (771) Anidulafungin 0.015/ Caspofungin 0.12/ Amphotericin B 0.5/ FC 0.5/ (0.1) 2.0 Fluconazole 0.5/ Itraconazole 0.03/ Posaconazole 0.06/ Voriconazole 0.06/ C. parapsilosis (238) Anidulafungin 2/ Caspofungin 0.5/ Amphotericin B 1/ FC 0.5/ (0.0) 1.3 Fluconazole 1/ Itraconazole 0.25/ Posaconazole 0.12/ Voriconazole 0.06/ C. glabrata (202) Anidulafungin 0.015/ Caspofungin 0.25/ Amphotericin B 1/ FC 0.5/ (0.0) 0.0 Fluconazole 8/ Itraconazole 1/ Posaconazole 1/ Voriconazole 0.25/ C. tropicalis (157) Anidulafungin 0.03/ Caspofungin 0.12/ Amphotericin B 1/ FC 0.5/ (0.6) 4.5 Fluconazole 0.5/ Itraconazole 0.12/ Posaconazole 0.12/ Voriconazole 0.06/ C. krusei (29) Anidulafungin 0.06/ Caspofungin 0.5/ d Amphotericin B 1/ FC 16/ (93.2) 3.4 Fluconazole 32/ Itraconazole 0.5/ Posaconazole 0.5/ Voriconazole 0.25/ C. lusitaniae (14) Anidulafungin 0.25/ Caspofungin 0.5/ Amphotericin B 0.5/ FC 0.5/ (0.0) 0.0 Fluconazole 0.5/ Continued on following page
3 1944 NOTES J. CLIN. MICROBIOL. TABLE 1 Continued Species (no. of isolates) and drug MIC 50 /MIC 90 ( g/ml) MIC range ( g/ml) % by category a S SDD R b Itraconazole 0.12/ M Posaconazole 0.06/ Voriconazole 0.06/ C. neoformans (33) Anidulafungin 32/ Caspofungin 16/ Amphotericin B 0.25/ FC 4/ Fluconazole 4/ Itraconazole 0.06/ Posaconazole 0.06/ Voriconazole 0.06/ a The breakpoint criteria used are those of the CLSI (2008). When testing amphotericin B, a susceptibility breakpoint of 1 g/ml was used. Each value in parentheses is the percent intermediate (CLSI, 2008), and a dash indicates that there is no established breakpoint. b There is no resistant category for echinocandins. The CLSI interpretive guidelines state that strains with echinocandin MICs of 2.0 g/ml are susceptible. MICs of 2.0 g/ml result in classification as not susceptible. c Data are not shown for C. dubliniensis (seven isolates), C. famata (six isolates), C. guilliermondii (nine isolates), C. kefyr (five isolates), C. pelliculosa (four isolates), and four Candida sp. isolates plus two unspecified isolates. d Represents a single isolate. 48 h (all other agents). The MICs of anidulafungin, caspofungin, 5-FC, fluconazole, itraconazole, and voriconazole were read as the lowest concentration at which a significant decrease in turbidity ( 50%) was discerned compared to that of the growth control. Amphotericin B MICs were determined as the lowest concentration at which no visible growth was detected (1). The interpretive breakpoints for susceptibility to anidulafungin and caspofungin (susceptible [S], 2 mg/liter; nonsusceptible [NS], 2 mg/liter), fluconazole (S, 8 mg/liter; susceptible dose dependent [SDD], 16 to 32 mg/liter; resistant [R], 64 mg/liter), 5-FC (S, 4 mg/liter; intermediate [I], 8 to 16 mg/liter; R, 32 mg/liter), itraconazole (S, mg/liter; SDD, 0.25 to 0.5 mg/liter; R, 1 mg/liter), and voriconazole S, 1 mg/liter; SDD, 2 mg/liter; R, 4 mg/liter) were those published by the CLSI (2). Interpretive criteria for amphotericin B and posaconazole have not been established, but for comparison, isolates inhibited by amphotericin B at 1 g/ml were considered susceptible. Mold testing panels were aerobically incubated at 35 C in an enclosed container and visualized with a reading mirror at 24 h (echinocandins) and 48 h (all other agents) under a biosafety hood. MICs of amphotericin B, itraconazole, posaconazole, and voriconazole were determined as the concentration at which no discernible growth was detected. MICs of 5-FC were determined as the lowest concentration at which a prominent decrease in growth ( 50%) was visualized compared to the growth control (3, 4). As described for anidulafungin (10) and caspofungin (11), minimal effective concentrations (MECs) were determined as the lowest concentration at which a pronounced morphological change from filamentous growth to nonfilamentous growth was observed. The rank order of the 1,448 Candida sp. isolates collected during the 2006 to 2007 SENTRY Program surveillance period (Table 1) from all geographic regions was C. albicans (53.2%) C. parapsilosis (16.4%), C. glabrata (13.9%), C. tropicalis (10.8%), C. krusei (2.0%), and other Candida spp. (3.5%). The species distribution was consistent with Candida spp. collected in prior SENTRY Program monitoring periods (1997 to 1999, 2003) (8, 9, 13). The antifungal activities (MIC 50 s and MIC 90 s, percent categorical interpretation) of the eight compounds tested against Candida spp. and C. neoformans are summarized in Table 1. The CLSI has not established breakpoints for agents in use against C. neoformans. However, posaconazole demonstrated the greatest activity (MIC 90, 0.12 g/ml) against this species. A. fumigatus was the most common (80.3%) of the Aspergillus spp. tested (Table 2). The agents most active against Aspergillus spp. included anidulafungin (MEC 90, g/ml), caspofungin (MEC 90, 0.12 g/ml), and posaconazole (MIC 90, 0.5 g/ml). An analysis of Candida species by continent of origin is summarized in Table 3 (APAC region data not shown). Among the four most common Candida species reported, those from North America and Europe had the same rank order (C. albicans C. glabrata C. parapsilosis C. tropicalis), which represents a shift in European species distribution from that in the previous SENTRY Program report (8, 9, 13). C. glabrata rose in prevalence rank from third to second in Europe, and TABLE 2. Activities of seven antifungal agents against 49 A. fumigatus strains collected by the SENTRY Program in 2006 to 2007 Agent MIC 50 /MIC 90 ( g/ml) MIC range ( g/ml) % of isolates inhibited by 1 g/ml a Anidulafungin 0.004/ Caspofungin 0.12/ Amphotericin B 2/ FC 64/ Itraconazole 1/ Posaconazole 0.5/ Voriconazole 0.5/ a Breakpoint criteria have not been established by the CLSI (2008). For comparison, the percent inhibited by 1 g/ml was used (3).
4 VOL. 47, 2009 NOTES 1945 TABLE 3. In vitro antifungal agent susceptibilities of Candida isolates collected by the SENTRY Program in 2006 to 2007 Species (no. tested) No. (%) of isolates or MIC 50/90 in g/ml (% susceptible) a North America Europe Latin America All Candida spp. 726 (50.1) 429 (29.6) 274 (18.9) Anidulafungin 0.03/2 (98.9) 0.03/1 (99.3) 0.03/1 (98.5) Caspofungin 0.12/0.5 (99.7) 0.12/0.5 (100.0) 0.12/0.5 (99.6) Amphotericin B 0.5/1 (99.9) 0.5/1 (99.5) 1/1 (98.9) 5-FC 0.5/ 0.5 (95.7) 0.5/ 0.5 (95.3) 0.5/ 0.5 (97.1) Fluconazole 0.5/8 (91.3) 0.5/8 (94.4) 0.5/2 (97.1) Itraconazole 0.06/1 (64.9) 0.06/1 (72.3) 0.06/0.5 (68.6) Posaconazole 0.06/1 0.06/1 0.06/0.25 Voriconazole 0.06/0.25 (97.9) 0.06/0.25 (98.4) 0.06/ 0.06 (99.3) C. albicans 377 (48.9) 260 (33.7) 126 (16.3) Anidulafungin 0.015/0.06 (100.0) 0.015/0.06 (100.0) 0.015/0.06 (100.0) Caspofungin 0.12/0.25 (100.0) 0.12/0.25 (100.0) 0.12/0.25 (100.0) Amphotericin B 0.5/1 (100.0) 0.5/1 (100.0) 0.5/1 (100.0) 5-FC 0.5/ 0.5 (96.8) 0.5/ 0.5 (98.8) 0.5/ 0.5 (99.2) Fluconazole 0.5/ 0.5 (99.5) 0.5/ 0.5 (100.0) 0.5/ 0.5(100.0) Itraconazole 0.03/0.12 (97.3) 0.03/0.06 (98.1) 0.03/0.12 (97.6) Posaconazole 0.06/ / /0.12 Voriconazole 0.06/ 0.06 (100.0) 0.06/ 0.06 (100.0) 0.06/ 0.06 (100.0) C. parapsilosis 122 (51.3) 53 (22.3) 60 (25.2) Anidulafungin 2/2 (93.4) 2/2 (94.3) 1/2 (98.3) Caspofungin 0.5/1 (99.2) 0.5/1 (100.0) 0.5/1 (100.0) Amphotericin B 1/1 (100.0) 1/1 (100.0) 1/1 (100.0) 5-FC 0.5/ 0.5 (99.2) 0.5/ 0.5 (100.0) 0.5/ 0.5 (96.7) Fluconazole 1/4 (95.9) 1/2 (100.0) 1/4 (95.0) Itraconazole 0.25/0.5 (43.4) 0.25/0.25 (43.4) 0.25/0.5 (30.0) Posaconazole 0.12/ / /0.25 Voriconazole 0.06/0.12 (100.0) 0.06/ 0.06(100.0) 0.06/0.12 (98.3) C. glabrata 133 (65.8) 57 (28.2) 11 (0.05) Anidulafungin 0.06/0.12 (100.0) 0.06/0.12 (100.0) 0.06/0.12 (100.0) Caspofungin 0.12/0.25 (100.0) 0.25/0.25 (100.0) 0.25/0.5 (100.0) Amphotericin B 1/1 (100.0) 1/1 (100.0) 1/1 (100.0) 5-FC 0.5/ 0.5 (100.0) 0.5/ 0.5 (100.0) 0.5/ 0.5 (100.0) Fluconazole 8/ 64 (71.4) 8/16 (78.9) 4/16 (81.8) Itraconazole 1/ 2 (2.3) 1/ 2 (5.3) 1/2 (9.1) Posaconazole 1/4 1/4 0.5/1 Voriconazole 0.25/2 (88.7) 0.25/1 (93.0) 0.12/0.5 (90.9) C. tropicalis 53 (33.7) 36 (22.9) 62 (39.5) Anidulafungin 0.03/0.06 (100.0) 0.03/0.6 (100.0) 0.03/0.06 (100.0) Caspofungin 0.12/0.5 (100.0) 0.12/0.25 (100.0) 0.12/0.5 (100.0) Amphotericin B 1/1 (100.0) 1/1 (100.0) 1/1 (95.2) 5-FC 0.5/ 0.5 (96.2) 0.5/ 0.5 (91.7) 0.5/ 0.5 (95.2) Fluconazole 0.5/1 (100.0) 0.5/1 (97.2) 0.5/ 0.5 (100.0) Itraconazole 0.12/0.5 (62.3) 0.12/0.5 (72.2) 0.12/0.5 (66.1) Posaconazole 0.12/ / /0.25 Voriconazole 0.06/ 0.06 (100.0) 0.06/ 0.06 (100.0) 0.06/ 0.06 (100.0) a The breakpoint criteria used are those of the CLSI (2008). When testing amphotericin B, a susceptibility breakpoint of 1 g/ml was used. No results are shown for categories with 10 isolates. the C. parapsilosis rank order dropped to third. The impact of the more frequent occurrence of C. glabrata in Europe has yet to be clarified, and further longitudinal surveillance to detect sustained trends in species distribution and antifungal susceptibility appears warranted. Shifts in species distribution were also observed in Latin America and the APAC region, where the 2006 to 2007 rank order of Candida spp. was C. albicans C. tropicalis C. parapsilosis C. glabrata. Among the 19 Candida isolates from the APAC region, no more than 8 were of one species (C. albicans). These yeasts had susceptibility rates ranging from 73.7% (itraconazole) to 100% (anidulafungin, caspofungin, amphotericin B, 5-FC). This report extends the longitudinal global surveillance results for yeast and mold species collected from bloodstream and sterile body site infections and closely monitors developments in species occurrences with antifungal susceptibility processed by established CLSI reference methods (1 3, 4, 15). As the use of routine antifungal testing by commercial or reference procedures remains a practice performed by a distinct minority of clinical laboratories (15), the use of national or
5 1946 NOTES J. CLIN. MICROBIOL. global antifungal surveillance networks clearly is a necessity to guide formulary choices (8, 9, 12, 13, 16). We thank K. Mellen, T. R. Fritsche, H. S. Sader, and A. Fuhrmeister for significant contributions to study analysis, technical support, and manuscript preparation. This work was funded by a grant from Pfizer, Inc. REFERENCES 1. Clinical and Laboratory Standards Institute M27-A3 reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, third edition. Clinical and Laboratory Standards Institute, Wayne, PA. 2. Clinical and Laboratory Standards Institute M27-S3 reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA. 3. Clinical and Laboratory Standards Institute M38-A2 reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, second edition. Clinical and Laboratory Standards Institute, Wayne, PA. 4. Espinel-Ingroff, A., A. Fothergill, M. A. Ghannoum, E. Manavathu, L. Ostrosky-Zeichner, M. A. Pfaller, M. G. Rinaldi, W. A. Schell, and T. J. Walsh Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J. Clin. Microbiol. 45: Hazen, K. C., and S. A. Howell Candida, Cryptococcus, and other yeasts of medical importance, p In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. American Society for Microbiology, Washington, DC. 6. Jones, R. N., J. T. Kirby, S. A. Messer, and D. J. Sheehan Development of anidulafungin for disk diffusion susceptibility testing against Candida spp. Diagn. Microbiol. Infect. Dis. 58: Krisher, K., S. Brown, and M. Traczewski Quality control parameters for broth microdilution tests of anidulafungin. J. Clin. Microbiol. 42: Messer, S. A., R. N. Jones, and T. R. Fritsche International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J. Clin. Microbiol. 44: Messer, S. A., J. T. Kirby, H. S. Sader, T. R. Fritsche, and R. N. Jones Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54: Odabasi, Z., V. L. Paetznick, J. R. Rodriguez, E. Chen, and L. Ostrosky- Zeichner In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 48: Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez- Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42: Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43: Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, and S. A. Messer International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 39: Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46: Pfaller, M. A., and R. N. Jones Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program ( ). Arch. Pathol. Lab. Med. 130: Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46: Verweij, P. E., and M. E. Brandt Aspergillus, Fusarium, and other opportunistic moniliaceous fungi, p In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. American Society for Microbiology, Washington, DC.
Received 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationReceived 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 70 75 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01551-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More informationReceived 21 July 2008/Accepted 3 September 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2008, p. 3585 3590 Vol. 46, No. 11 0095-1137/08/$08.00 0 doi:10.1128/jcm.01391-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Validation
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationon November 3, 2018 by guest
JOURNAL OF CLINICAL MICROBIOLOGY, June 2007, p. 1811 1820 Vol. 45, No. 6 0095-1137/07/$08.00 0 doi:10.1128/jcm.00134-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationReceived 25 September 2006/Returned for modification 4 December 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 796 802 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01986-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationComparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species
NEW MICROBIOLOGICA, 31, 257-262, 2008 Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species Anna Serefko, Renata Los, Anna
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationInterlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2004, p. 3475 3482 Vol. 42, No. 8 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.8.3475 3482.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationon December 11, 2018 by guest
JCM Accepts, published online ahead of print on 12 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.03125-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Biographical Feature;
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationMETHODS: MINIMAL INHIBITORY AND FUNGICIDAL CONCENTRATION AND TIME-KILLING STUDIES. Gobernado b. Fe, Valencia 46009, Spain.
AAC Accepts, published online ahead of print on 20 April 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.00160-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationRapid Antifungal Susceptibility Determination for Yeast Isolates by Use of Etest Performed Directly on Blood Samples from Patients with Fungemia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2010, p. 2205 2212 Vol. 48, No. 6 0095-1137/10/$12.00 doi:10.1128/jcm.02321-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Rapid Antifungal
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationon December 9, 2018 by guest
JCM Accepts, published online ahead of print on 27 June 2012 J. Clin. Microbiol. doi:10.1128/jcm.00937-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Progress in Antifungal
More informationJapan Antifungal Surveillance Program (1):
183 Japan Antifungal Surveillance Program (1): 2001 2002 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 16 9 14 16 10 12 2001 6 2002 3 2 11 576 fluconazole (FLCZ),
More informationMultilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1543 1548 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.01510-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multilaboratory
More informationAAC Accepts, published online ahead of print on 21 March 2011 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 1 March 0 Antimicrob. Agents Chemother. doi:./aac.010- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationEchinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2516 2521 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationUpdate zu EUCAST 2012 Cornelia Lass-Flörl
Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical
More informationReceived 5 August 2004/Accepted 26 September 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 512 517 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.512 517.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationResearch Article In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed by the Reference Broth Microdilution Method
The Scientific World Journal Volume 2013, Article ID 236903, 6 pages http://dx.doi.org/10.1155/2013/236903 Research Article In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationAntifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units
Journal of Medical Microbiology (2012), 61, 389 393 DOI 10.1099/jmm.0.037895-0 Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian
More informationInterlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: Should the clinical laboratory be testing this agent?
AAC Accepts, published online ahead of print on 9 September 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01519-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationEUCAST-AFST Available breakpoints 2012
EUCAST-AFST Available breakpoints th NSMM meeting Göteborg, Sweden October th EUCAST-AFST documents Reference Methods Yeast E.DEF. () TN- E.DEF. (CMI epub July) E.DEF. () TN- E.DEF. () Breakpoints Compound
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationAbout the Editor Gerri S. Hall, Ph.D.
About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,
More informationReceived 12 May 2010/Returned for modification 24 June 2010/Accepted 6 July 2010
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2010, p. 3153 3157 Vol. 48, No. 9 0095-1137/10/$12.00 doi:10.1128/jcm.00952-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative
More informationAmphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01310.x Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital A. Bedini 1, C. Venturelli 2, C. Mussini 1, G.
More informationThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Therapeutics Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Impact of the New Clinical Breaking Points Proposed
More informationEchinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical
JCM Accepts, published online ahead of print on 29 May 2013 J. Clin. Microbiol. doi:10.1128/jcm.00308-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 JCM00308-13 REVISION
More informationReceived 7 March 2002/Returned for modification 16 April 2002/Accepted 13 June 2002
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2002, p. 3204 3208 Vol. 40, No. 9 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.9.3204 3208.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationIn Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2008, p. 150 156 Vol. 46, No. 1 0095-1137/08/$08.00 0 doi:10.1128/jcm.01901-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro Susceptibility
More informationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationAntifungal Susceptibility Testing of Candida Isolates from the Candida Surveillance Study
Antifungal Susceptibility Testing of Candida Isolates from the Candida Surveillance Study G Marshall Lyon III, Emory University Sulaiman Karatela, Emory University Susan Sunay, Emory University Yaffa Adiri,
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationSensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure
Basic research Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure Anna Serefko, Anna Malm Department of Pharmaceutical Microbiology, Medical
More informationReceived 29 October 2009/Returned for modification 4 January 2010/Accepted 9 February 2010
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2010, p. 1366 1377 Vol. 48, No. 4 0095-1137/10/$12.00 doi:10.1128/jcm.02117-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Results from
More informationReceived 6 October 2010/Returned for modification 26 December 2010/Accepted 7 January 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1580 1587 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.01364-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationThe Evolving Role of Antifungal Susceptibility Testing. Gregory A. Eschenauer and Peggy L. Carver
S PECIAL A RTICLE The Evolving Role of Antifungal Susceptibility Testing Gregory A. Eschenauer and Peggy L. Carver Although increasing numbers of hospital microbiology laboratories are performing antifungal
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationFluconazole Susceptibility Profile of Candida isolates Recovered from Patients Specimens Admitted to Yazd Central Laboratory
Iranian Journal of Pharmaceutical Research (2008), 7 (1): 69-75 Received: June 2007 Accepted: November 2007 Copyright 2008 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health
More informationANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 198 202 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activity of the New Triazole Voriconazole (UK-109,496)
More informationyour lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.
626 CE update [microbiology and virology] Antifungal Susceptibility Methods and Their Potential Clinical Relevance Ana Espinel-Ingroff, PhD Medical College of Virginia, Virginia Commonwealth University,
More informationACCEPTED JCM REVISED. In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and
JCM Accepts, published online ahead of print on 1 November 00 J. Clin. Microbiol. doi:./jcm.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationTriazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2006, p. 529 535 Vol. 44, No. 2 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.2.529 535.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Triazole
More informationAvailable online at journal homepage:
Kaohsiung Journal of Medical Sciences (2012) 28, 306e315 Available online at www.sciencedirect.com journal homepage: http://www.kjms-online.com ORIGINAL ARTICLE Fluconazole exposure rather than clonal
More informationIn Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2007, p. 1616 1620 Vol. 51, No. 5 0066-4804/07/$08.00 0 doi:10.1128/aac.00105-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. In Vivo
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationBSI. Candida auris: A globally emerging multidrug-resistant yeast 5/19/2017. First report of C. auris from Japan in 2009
5/9/7 BSI Candida auris: A globally emerging multidrug-resistant yeast Mycotic Diseases Branch DFWED Friday Seminar August 6, 6 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationJCM Accepts, published online ahead of print on 3 February 2010 J. Clin. Microbiol. doi: /jcm
JCM Accepts, published online ahead of print on 3 February 2010 J. Clin. Microbiol. doi:10.1128/jcm.02363-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationCandidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex
Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex ORIGINAL ARTICLE ABSTRACT Introduction: Although the spectrum of fungi causing bloodstream fungal infections
More informationIdentification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey
DOI 10.1186/s12941-016-0153-1 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Identification and antifungal susceptibility of Candida species isolated from bloodstream infections
More informationRapid Species Identification and Antifungal Susceptibility Testing of Candida Isolated from Different Hospital Acquired Infections by VITEK 2 System
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 11 (2017) pp. 764-772 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.611.090
More informationDepartment of Pathology, University of Iowa College of Medicine, Iowa City, 1 and The JONES Group/JMI Laboratories, North Liberty, 2 Iowa
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2002, p. 1032 1037 Vol. 46, No. 4 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.4.1032 1037.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationAntifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside
REVIEW 10.1111/1469-0691.12495 Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside M. Cuenca-Estrella National Center for Microbiology, Instituto de Salud Carlos III, Madrid,
More informationReceived 1 December 2009/Accepted 26 January 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2010, p. 1541 1546 Vol. 54, No. 4 0066-4804/10/$12.00 doi:10.1128/aac.01688-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Evaluation
More informationSusceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006
Available online at www.sciencedirect.com Diagnostic Microbiology and Infectious Disease 61 (2008) 175 180 Mycology www.elsevier.com/locate/diagmicrobio Susceptibilities to amphotericin B and fluconazole
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationSpecies distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study
J Antimicrob Chemother 2013; 68: 2847 2851 doi:10.1093/jac/dkt283 Advance Access publication 18 July 2013 Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric
More informationUse of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species
Brazilian Journal of Microbiology 44, 4, 1257-1266 (2013) ISSN 1678-4405 Copyright 2013, Sociedade Brasileira de Microbiologia www.sbmicrobiologia.org.br Research Paper Use of the VITEK 2 system to identify
More informationNew triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
For reprint orders, please contact reprints@expert-reviews.com New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance Expert Rev. Anti Infect. Ther. 7(8), 981 998
More informationReceived 25 March 2008/Returned for modification 12 May 2008/Accepted 15 June 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2008, p. 2620 2629 Vol. 46, No. 8 0095-1137/08/$08.00 0 doi:10.1128/jcm.00566-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Correlation
More informationEpidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients
OPEN (2017) 6, e87; doi:10.1038/emi.2017.74 www.nature.com/emi ORIGINAL ARTICLE Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients Ping-Feng
More informationCandidemia: New Sentinel Surveillance in the 7-County Metro
Candidemia: New Sentinel Surveillance in the 7-County Metro Brittany VonBank, MPH Paula Vagnone, MT (ASCP) 651-201-5414 www.health.state.mn.us Health Care-associated Infections & Antimicrobial Resistance
More informationon March 29, 2019 by guest
JCM Accepts, published online ahead of print on 4 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationSpecies distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002
Fluconazole J Microbiol Immunol susceptibility Infect of Candida 2004;37:236-241 Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002 Jiun-Ling Wang
More informationDepartment of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran 3
Curr Med Mycol, 2016 Jun, 2(2): 34-39 Article Original In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran Shokohi T 1,2, Badali H 1,2, Amirrajab N 3, Ataollahi MR
More informationEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
Journal of Antimicrobial Chemotherapy (2008) 62, 1094 1100 doi:10.1093/jac/dkn304 Advance Access publication 25 July 2008 Evaluation of aminocandin and caspofungin against Candida glabrata including isolates
More informationNational Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention Invasive Candidiasis
More information9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Invasive Candidiasis Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention
More informationThe antifungal susceptibilities of oral Candida spp isolates from HIV-infected patients
Advanced Journal of Microbiology Research Volume 2015 Available online at http://advancedresearchjournals.org/ajmr Advanced Research Journals Full Length Research Paper The antifungal susceptibilities
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationAna Espinel-Ingroff 1, Elizabeth Johnson 2, Hans Hockey 3 and Peter Troke 4 *
Journal of Antimicrobial Chemotherapy (2008) 61, 616 620 doi:10.1093/jac/dkm518 Advance Access publication 25 January 2008 Activities of voriconazole, itraconazole and amphotericin B in vitro against 590
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationCandida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains
Medical Mycology March 2009, 47, 137143 Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains MARÍA MERCEDES PANIZO, VERA REVIÁKINA,
More informationglabrata, Candida bracarensis and Candida nivariensis evaluated by time-kill studies
AAC Accepted Manuscript Posted Online March Antimicrob. Agents Chemother. doi:./aac.- Copyright, American Society for Microbiology. All Rights Reserved. In vitro fungicidal activities of anidulafungin,
More informationLaboratory evaluation for determining posaconazole susceptibility of fungi isolated in denture stomatitis
Experimental immunology DOI: 10.5114/ceji.2013.35209 Laboratory evaluation for determining posaconazole susceptibility of fungi isolated in denture stomatitis MARTA JAWORSKA-ZAREMBA 1, EL BIETA MIERZWIÑSKA-NASTALSKA
More informationReceived 12 May 2009/Returned for modification 22 June 2009/Accepted 12 August 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2009, p. 3170 3177 Vol. 47, No. 10 0095-1137/09/$08.00 0 doi:10.1128/jcm.00942-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. In Vitro
More informationACCEPTED DIFFERENTIAL FUNGICIDAL ACTIVITY OF AMPHOTERICIN B AND VORICONAZOLE AGAINST ASPERGILLUS SPECIES DETERMINED BY MICROBROTH METHODOLOGY
AAC Accepts, published online ahead of print on 18 June 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.00345-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationReview. Ana Espinel-Ingroff
Review Rev Iberoam Micol 2003; 20: 121-136 121 In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods
More informationIn Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1318 1324 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01159-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationPotato Dextrose Agar Antifungal Susceptibility Testing for Yeasts and Molds: Evaluation of Phosphate Effect on Antifungal Activity of CMT-3
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2002, p. 1455 1461 Vol. 46, No. 5 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.5.1455 1461.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationAntifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients
ISSN: 2319-7706 Volume 4 Number 3 (2015) pp. 716-720 http://www.ijcmas.com Original Research Article Antifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients Deepak Kumar 1, Sayan
More informationEpidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review
Epidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review Haydar A a a Department of Internal Medicine, Kulliyyah of Medicine,
More informationUpdate on Candida Infection Nov. 2010
Update on Candida Infection Nov. 2010 Gary Wong Pharmacy Clinical site leader University Health Network Course coordinator University of Toronto Goals What is an yeast infection Risk factors for yeast
More information